On December 22, 1988, the Food and Drug Administration licensed an
additional Haemophilus b Conjugate Vaccine for routine use in
children
greater than or equal to18 months of age. The manufacturer is
expected
to begin distribution of the Haemophilus b Conjugate Vaccine
(Diphtheria CRM197 Protein Conjugate) within a few weeks.
Recommendations of the Immunization Practices Advisory Committee
for
the use of Haemophilus b Conjugate Vaccine (Diphtheria Toxoid
Conjugate) (1) are applicable to the new conjugate vaccine.
Reference
ACIP. Update: prevention of Haemophilus influenzae type b
disease.
MWMR 1988;37:13-6.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
